シスプラチン・エピルビシン・リピオドールエマルジョンによる肝細胞癌の動注化学療法

概要

論文の詳細を見る
Intra-arterial injection therapy with multi-anticancer drug for hepatocellular carcinoma has been conducted frequently. We prepared Cisplatin (CDDP)-Epirubicin(EPI)-Lipiodol Emulsion (CELE)in 1990 and have used in this therapy ever since. We examined clinical evaluation for CELE including survival rate, while pharmaceutical evaluation for stability and size of particles of CELE with image analyzer lately. These average particle diameters of CELE were as follows : Iopamiron 300, a non-ionic contrast medium, 1.4 <I>μ</I>m : Urografin 76, an ionic contrast medium, 10∼150 <I>μ</I>m, respectively. CELE used Iopamiron 300 was retained emulsification over three hours after preparation. CDDP and EPI in CELE were taken into liver 85% and 35% of total dose, respectively. Two years survival rate treated transcatheter arterial embolization with CELE was improved from about 10% to 70% as compared with Cisplatin-Lipiodol-suspension. No severe side effects were observed with CELE.